Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 701–800 of 999
Tosun, D., Thropp, P., Southekal, S. S., Spottiswoode, B. S., Fahmi, R., & Initiative, A. D. N. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13164 · Cited by 9
Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist
Kaur, G., Dar, Z. A., Bajpai, A., Singh, R., & Bansal, R. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.08.013 · Cited by 9
Wang, G., Hassenstab, J. J., Li, Y., Aschenbrenner, A. J., McDade, E., Llibre‐Guerra, J. J., Bateman, R. J., & Xiong, C. (2024) · Statistics in Medicine · doi:10.1002/sim.10292 · Cited by 8
“These assumptions are reasonable in that the duration, the assessment schedule, the dropout rate, and the treatment effect have been used in or are similar to previous trials [25–27].”
Are we ready to use anti-amyloid therapy in Alzheimer's disease?
Brucki, S. M. D., César‐Freitas, K. G., Spera, R. R., Borges, C. R., & Smid, J. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2022-s117 · Cited by 10
The Glymphatic System: A Review
Oliveira, L. M., Figueiredo, E. G., & Peres, C. M. A. (2018) · Arquivos Brasileiros de Neurocirurgia Brazilian Neurosurgery · doi:10.1055/s-0038-1667052 · Cited by 9
Cognitive go/No-go decision-making criteria in Alzheimer’s disease drug development
Wessels, A. M., Edgar, C. J., Nathan, P. J., Siemers, E. R., Maruff, P., & Harrison, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.012 · Cited by 7
Self-citationNavigating the treatment landscape of Alzheimer's disease: Current strategies and future directions
Mohapatra, T. K., Nayak, R. R., Ganeshpurkar, A., Tiwari, P. K., & Kumar, D. (2025) · Ibrain · doi:10.1002/ibra.12197 · Cited by 9
“131,132 While some initial data suggested a possible benefit in mild AD (EXPEDITION 1), this wasn't confirmed in subsequent trials (EXPEDITION 2 & 3).”
Zhou, Y., Yu, G., & Li, H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324202 · Cited by 9
“The deposition of A β is the most important pathological feature and one of the critical causes of neurological damage in AD [33].”
Chen, C. D., Franklin, E. E., Li, Y., Joseph‐Mathurin, N., Burns, A., Hobbs, D. A., McCullough, A. A., Schultz, S. A., Xiong, C., Wang, G., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02890-7 · Cited by 9
“In response, many treatment strategies for AD have focused on Aβ as a drug target, spurring the development of several anti-Aβ monoclonal antibody-based therapeutics [27, 33, 37, 51, 55].”
Self-citationAdvances of therapeutic strategies for Alzheimer’s disease
Guo, X., Yue, R.-Z., Cui, Z., Wang, S., Jia, T., Li, W., Zhang, W., Shan, L., & Li, C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13456-8 · Cited by 10
“Solanezumab binds exclusively to Aβ monomers, since it recognizes the intermediate sequence epitope, which is enclosed in oligomers and fibrils [33].”
Kim, M., Kwon, H., Sohn, S., Lee, W. J., Cho, K., & Kim, G. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251391820 · Cited by 13
He, C.-Y., Tian, D., Chen, S.-H., Jin, W., Cheng, Y., Xin, J., Li, W., Zeng, G., Tan, C., Jian, J.-M., et al. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00936-4 · Cited by 8
Neve, A., Das, B., Wojtowicz, J., Huang, Z., Bullain, S., Watkin, M., Lott, D., Bittner, T., Delmar, P., Klein, G., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240221 · Cited by 8
Alzheimer’s Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies
Hales, C. M. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.10.003 · Cited by 7
Siemers, E., Feaster, T., Sethuraman, G., Sundell, K. L., Skljarevski, V., Cline, E. N., Zhang, H., Jerecìć, J., Honig, L. S., Salloway, S., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100005 · Cited by 8
Self-citationLozupone, M., Dibello, V., Resta, E., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Mollica, A., Berardino, G., et al. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2500752 · Cited by 9
“A situation similar a what happened when Eli Lilly & Co. conducted a third Phase III RCT on solanezumab (Expedition3) after two previous trials (Expedition1 and 2) producing negative/equivocal findings, and this again proved negative [69].”
Bali, P., Bammidi, S., Banik, A., Nehru, B., & Anand, A. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00222 · Cited by 7
“Eli Lilly developed a drug solanezumab, targeting amyloid with an aim to delay the progression of AD and then subjected it to clinical trials, which eventually were terminated prematurely (Honig et al., 2018).”
BackgroundAlzheimer’s Disease Pharmacology
Plascencia‐Villa, G., & Perry, G. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00018-9 · Cited by 8
Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit
Frölich, L., & Hausner, L. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01222-w · Cited by 13
Koob, A. O. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2104112 · Cited by 9
Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
Therriault, J., Lussier, F. Z., Tissot, C., Chamoun, M., Stevenson, J., Rahmouni, N., Pallen, V., Bezgin, G., Servaes, S., Kunach, P., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12391 · Cited by 8
Drugs for Alzheimer’s disease: Where are we coming from? Where are we going?
Angioni, D., Delrieu, J., Coley, N., Ousset, P., Shi, J., & Vellas, B. J. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.02.021 · Cited by 7
Self-citationLes nouveaux traitements de la maladie d’Alzheimer
Delrieu, J., & Vellas, B. J. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.01.018 · Cited by 13
Self-citationKim, S., Kim, K., Nho, K. T., Myung, W., & Won, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200671 · Cited by 7
New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimer’s Disease
Zhuo, J., Zhang, Y., Liu, Y., Liu, B., Zhou, X. A., Bartlett, P. F., Jiang, T., & Initiative, A. D. N. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab017 · Cited by 9
“2003 used in the mild AD stage (Honig et al. 2018), which is too late to prevent rapid cognitive decline.”
Xia, X., Li, C., Wang, Y., Deng, X., Ma, Y., Ding, L., & Zheng, J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-0184-6 · Cited by 7
Ballard, C. G., Creese, B., Gatt, A. P., Doherty, P., Francis, P. T., Whitfield, D., Corbett, A., Corcoran, J., Hanger, D. P., Thuret, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622308 · Cited by 7
What the gantenerumab trials teach us about Alzheimer's treatment
Schneider, L. S. (2023) · New England Journal of Medicine · doi:10.1056/nejme2310903 · Cited by 6
Anti-Amyloid Drugs for Alzheimer’s Disease: Considering the Role of Depression
Moyano, B. P., Zullo, L., Rouaud, O., Vandel, P., von Gunten, A., & Allali, G. (2024) · Neurodegenerative Diseases · doi:10.1159/000541783 · Cited by 7
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
McCullough, A. A., Chen, C. D., Gordon, B. A., Joseph‐Mathurin, N., Jack, C. R., Koeppe, R., Hornbeck, R. C., Koudelis, D., McKay, N. S., Hobbs, D. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70347 · Cited by 9
“1,2 5 The primary approaches to lowering A β have been either the use of drugs that alter β -site amyloid precursor protein cleavage (BACE inhibitors 6–9 ) or monoclonal antibody therapies that recognize monomeric (e.g., solanezumab 10,11 ) or aggregated forms of A β (e.g., gantenerumab 12–14 ).”
Self-citationRelationship between efficacy and preferential targeting of soluble Aβ aggregates
Kaplan, J. M., Gibbs, E., Coutts, J. A., Zhao, B., Mackenzie, I. R., Plotkin, S. S., & Cashman, N. R. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70184 · Cited by 10
“Targeting monomers with solanezumab failed to impact cognitive decline, 38 and it has been suggested that maintaining high levels of A β 42 monomers in the central nervous system may actually benefit synaptic plasticity and memory.”
Ma, X., Shyer, M. N., Harris, K., Wang, D., Hsu, Y., Farrell, C. M., Goodwin, N., Anjum, S., Bukhbinder, A. S., Dean, S., et al. (2024) · PLOS Digital Health · doi:10.1371/journal.pdig.0000479 · Cited by 10
Hou, Z., Sun, A., Li, Y., Song, X., Liu, S., Hu, X., Luan, Y., Guan, H., He, C., Sun, Y., et al. (2024) · Mediators of Inflammation · doi:10.1155/2024/7709277 · Cited by 7
“Clinically, the diagnostic methods of cognitive disorders mainly include the MoCA, ADL, CDR, HIS, and other scales [17, 18]; magnetic resonance imaging (MRI) [19, 20]; and 18 F-labeled deoxyglu-cose PET ( 18 FDG-PET) technology [21].”
Predicting regional tau accumulation with machine learning‐based tau‐PET and advanced radiomics
Rathore, S., Higgins, I. A., Wang, J., Kennedy, I. A., Iaccarino, L., Burnham, S. C., Pontecorvo, M. J., & Shcherbinin, S. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70005 · Cited by 10
Bocchieri, E., Zimbone, S., Giuffrida, M. L., Natale, G. D., Sabatino, G., Vecchio, G., Pappalardo, G., & Chiechio, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177274 · Cited by 6
Xue, R., Gao, P., Chen, Y.-M., Liu, Y., Han, B., Huang, Y., Mi, Y., Cui, R., Lin, Y., Wang, Z.-T., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322808 · Cited by 6
Autoradiographic comparison between [11C]PiB and [18F]AZD4694 in human brain tissue
Aliaga, A., Therriault, J., Quispialaya, K. M., Aliaga, A., Kunach, P., Macedo, A. C., Hopewell, R., Rahmouni, N., Soucy, J., Massarweh, G., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01216-8 · Cited by 5
“Furthermore, the several additional monoclonal antibodies currently under evaluation in AD [8, 47] support the expectation that molecular brain imaging in neurodegenerative disease may become a routine clinical tool in the coming years [48].”
Medikamentöse Prävention von kognitiver Verschlechterung und Demenz
Jessen, F. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03120-z · Cited by 6
Mansfield, C. A., Bullok, K. E., Fuhs, J. V., Tockhorn‐Heidenreich, A., Andrews, J. S., DiBenedetti, D. B., Matthews, B. R., Darling, J. C., Sutphin, J., & Hauber, B. (2022) · Patient · doi:10.1007/s40271-022-00576-w · Cited by 7
“Thus, the change from “some” to “more” problems was developed to represent a modest change in the ADAS-Cog and was based on medical judgment of what could reasonably occur over the natural course of AD and on observations from some clinical trials of investigational disease-modifying treatments for early AD [13, 32, 3…”
BackgroundMethodRetrospective Bayesian Evidence of Null Effect in Two Decades of Alzheimer’s Disease Clinical Trials
Costa, T., Manuello, J., Cauda, F., & Liloia, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220942 · Cited by 6
Zhang, W., Wang, H.-F., Kuo, K., Wang, L., Li, Y., Yu, J., Feng, J., & Cheng, W. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12992 · Cited by 7
Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases
Nainu, F., Mamada, S. S., Harapan, H., & Emran, T. B. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_3 · Cited by 6
Xiao, M., Wang, X., He, C., Huang, Z.-S., Chen, H., & Kong, L.-H. (2023) · PubMed Central · doi:10.22038/ijbms.2023.66954.14683 · Cited by 10
“Recently, several clinical trials of new drug treatments for AD have ended in failure (6), possibly due to the tardiness of intervention and the advanced stage of the disease.”
Beta Amyloid Oligomers with Higher Cytotoxicity have Higher Sidechain Dynamics
Yeh, C., Chang, H., Hsu, W., Huang, S., Wu, M., Tu, L., Lee, M., & Chan, J. C. C. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202301879 · Cited by 7
Future Treatment of Alzheimer Disease
Keskin, A. O., Durmaz, N., Uncu, G., Erzurumluoglu, E., Yıldırım, Z., Tuncer, N., & Adapınar, D. Ö. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85096 · Cited by 9
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy
Levites, Y., Funk, C. C., Wang, X., Chakrabarty, P., McFarland, K. N., Bramblett, B., O’Neal, V., Liu, X., Ladd, T. B., Robinson, M., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00453-4 · Cited by 6
“Indeed, even in humans, robust peripheral target engagement of soluble Aβ with the central domain monomer selective antibody, solanezumab, has failed to reduce amyloid plaques and was not associated with significant functional or cognitive benefit in mild AD [15, 31].”
BackgroundNovel strategies for the fight of Alzheimer’s disease targeting amyloid-β protein
Xie, Y., Wang, Y., Jiang, S., Xiang, X., Wang, J., & Ning, L. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1973482 · Cited by 7
“Nevertheless, most of these clinical trials have failed to achieve the desired results in cognitive improvement [34,96].”
BackgroundSetti, S. E., & Reed, M. N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00848-8 · Cited by 8
“While much of the research over the past few decades has focused on beta-amyloid pathology as a therapeutic target for the treatment of AD, therapeutic interventions focusing solely on beta-amyloid have proven largely unsuccessful (Higuchi et al. 2005; Holmes et al. 2008; Honig et al. 2018; Rosenblum 2014; Salloway et…”
BackgroundLarasati, V. A., Lembang, G. V., Tjahjono, Y., Winarsih, S., Ana, I. D., Wihadmadyatami, H., & Kusindarta, D. L. (2022) · Veterinary Sciences · doi:10.3390/vetsci9020048 · Cited by 10
“Lilly’s anti-amyloid-beta (solanezumab) failed to improve cognition in AD patients in a phase III clinical trial [16].”
BackgroundMozersky, J. T., AGREED, O. B. O., Roberts, J. S., Rumbaugh, M. C., Chhatwal, J. P., Wijsman, E. M., Galasko, D. R., & Blacker, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220113 · Cited by 8
On the Biomarkers of Alzheimer’s Disease
Liu, T. C., Zheng, T., Duan, R., Zhu, L., & Zhang, Q.-G. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34461-0_52 · Cited by 7
Aohara, K., Minatani, S., Kimura, H. M., Takeuchi, J., Takeda, A., Kawabe, J., Wada, Y., Mawatari, A., Watanabe, Y., Shimada, H., et al. (2019) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12366 · Cited by 6
Molecular Networks and Key Regulators of the Dysregulated Neuronal System in Alzheimer’s Disease
Wang, M., Li, A., Sekiya, M., Beckmann, N. D., Quan, X., Schrode, N., Fernando, M. B., Yu, A., Zhu, L., Cao, J., et al. (2019) · doi:10.1101/788323 · Cited by 6
Japanese participant data from three gantenerumab trials in early Alzheimer's disease
Asada, T., Thanasopoulou, A., Delmar, P., Wojtowicz, J., Smith, J., Yoshiyama, Y., Yokoi, K., Watanabe, C., Isozaki, M., Ozaki, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70192 · Cited by 5
Li, H., Zhao, Z., Fassini, A., Lee, H. K., Green, R. J., & Gomperts, S. N. (2025) · Scientific Reports · doi:10.1038/s41598-025-05653-2 · Cited by 9
“Even so, these treatments as yet have only modestly improved cognitive outcomes of AD patients 2,3,5 .”
Liu, Y., Chen, S., Li, S., Pei, Z., Fan, S., & Guo, Y. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251362444 · Cited by 9
Taragano, F. E., Seinhart, D. B., Epstein, P., Sylvestre, V., Barañano, C., Castro, V. O., Sánchez, V., Kilstein, A., González, R., Franco‐Trecu, V., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251375430 · Cited by 6
Wei, Y., & Li, H. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70017 · Cited by 5
“This outcome was evaluated in all 24 studies (Bateman et al. 2023; Budd et al. 2022; Doody et al. 2014; Honig et al. 2018; Ostrowitzki et al. 2022, 2017; Salloway et al. 2021, 2014; Sims et al. 2023; Sperling et al. 2023; van Dyck et al. 2023; Vanden-berghe et al. 2016).”
InfluentialEmerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Panwar, A., Khan, M. I. K., Kumar, R., Kumar, R., Kumar, S., & Kumar, A. (2024) · Advances in Alzheimer s Disease · doi:10.4236/aad.2024.133006 · Cited by 5
The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment
Dabur, M., Loureiro, J. A., & Pereira, M. D. C. (2022) · Biochimie · doi:10.1016/j.biochi.2022.08.003 · Cited by 6
Kainuma, M., Ouma, S., Kawakatsu, S., Iritani, O., Yamashita, K.-I., Ohara, T., Hirano, S., Suda, S., Hamano, T., Hieda, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.991982 · Cited by 8
“, 2012), but no clinical study of aducanumab or other antibody drugs that have been done in recent years on patients with mild AD have shown MCID in ADAS-Jcog exceeding 2 points (Doody et al., 2014; Honig et al., 2018; US Food and Drug Administration., 2020; Mintun et al., 2021), and no consensus has been reached on M…”
BackgroundTreatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias
Perlett, L., & Smith, E. E. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.07.008 · Cited by 6
Park, S., Lee, S. H., Zhao, H., Kim, J., Jang, J. Y., Choi, Y., Jeong, S., Son, S., Jung, K., & Jang, J.-H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1108371 · Cited by 6
“, 2016) for Aβ clearance and immunotherapy (Honig et al., 2018) have been recently attempted.”
BackgroundCircadian rhythm disruption and retinal dysfunction: a bidirectional link in Alzheimer's disease?
Carrero, L., Antequera, D., Municio, C., & Carro, E. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390962 · Cited by 6
“Although they were able to reduce Aβ deposition (Klein et al., 2019) they did not reach the primary endpoint because they cannot delay the progression of the disease (Honig et al., 2018; Alexander et al., 2021; Knopman et al., 2021).”
BackgroundLiu, W., Rao, X., Sun, W., Chen, X., Yu, L., Zhang, J., Chen, J., & Zheng, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05164-0 · Cited by 6
“…years, a number of studies have tested several agents that reduce Aβ production, impede Aβ aggregation, and increase Aβ clearance in the brain of patients with mild or moderate AD, including Crenezumab [23], Gantenerumab [24, 25], Solanezumab [26], Verubecestat [27, 28], and Lanabecestat [29].”
Hipótese amiloide e o tratamento da doença de Alzheimer: revisão dos estudos clínicos realizados.
Delanogare, E., Flores, D., de Souza, R. M., Souza, L. D., & Moreira, E. L. G. (2019) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v31i1.8395 · Cited by 16
Current clinical approaches in neurodegenerative diseases
Gago, M. F., Machado, Á. S., & Rocha, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00004-0 · Cited by 5
Wang, K., Na, L., & Duan, M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200916123000 · Cited by 6
Pathways in the Drug Development for Alzheimer’s Disease (1906-2016): A Bibliometric Study
Schilder, I. P. A., Veening-Griffioen, D. H., Ferreira, G. S., van Meer, P. J. K., Wied, C. C. G., Schellekens, H., Boon, W., & Moors, E. H. M. (2020) · Journal of Scientometric Research · doi:10.5530/jscires.9.3.35 · Cited by 5
“290 Journal of Scientometric Research, Vol 9, Issue 3, Sep-Dec 2020 inhibitors, whereby no cognitive improvements were shown despite a reduction of amyloid-beta,[64-66] have broadened the attention to non-amyloid and holistic approaches.”
BackgroundThe Ups and Downs of Amyloid in Alzheimer's
Siemers, E., Aisen, P. S. S., & Carrillo, M. C. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.54 · Cited by 5
“Trial results show that the antibody is associated with substantial plaque reduction based on amyloid PET and the fact that it causes ARIA.”
BackgroundResultInfluentialSelf-citationDiagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe
Black, S. A. G., Stepanchuk, A. A., Templeton, G. W., Hernandez, Y., Ota, T., Roychoudhury, S., Smith, E. E., Barber, P. A., Ismail, Z., Fischer, K., et al. (2022) · UCL Discovery (University College London) · Cited by 5
Neuroprotection in Alzheimer Disease
Jain, K. K. (2019) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4939-9465-6_8 · Cited by 6
Haddadi, P., Mahdavi, M., & Rahbarghazi, R. (2020) · Process Biochemistry · doi:10.1016/j.procbio.2020.01.010 · Cited by 6
AD and its comorbidities: An obstacle to develop a clinically efficient treatment?
Baker, J., & Schott, J. M. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.001 · Cited by 5
RANDOLPH, C. C. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.08.012 · Cited by 6
Renteros-Ramirez, M. S., Barreto-Abanto, R., Huapaya, D. C., Tovar-Cobos, M., Alvarado-Ramos, R. D., Rivera‐Lozada, O., & Barboza, J. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17080999 · Cited by 4
Maheta, P., Patel, C. A., Parmar, D., Beladiya, J., Patel, S. K., Sheth, D. B., & Dholakia, S. P. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00540 · Cited by 4
Li, D., Ao, X., Guan, Y., Qiu, Q., Ren, Y., & Zhang, N. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106921 · Cited by 5
The Role of Oligodendrocytes in Alzheimer’s Disease Pathogenesis and Therapy
Guo, S., Yu, X., & Zhang, H. (2025) · Neuroglia · doi:10.3390/neuroglia6040046 · Cited by 5
“Despite massive investment, therapies that blunt A β production, boost its clearance, block tau phosphorylation, or break tau aggregates have consistently failed to deliver meaningful clinical benefit in Phase III studies [155–158].”
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 6
Role of gasotransmitters in necroptosis
Cao, L., Wang, X., Chu, T., Wang, Y., Fan, Y.-Q., Chen, Y.-H., Zhu, Y., Zhang, J., Ji, X., & Wu, D. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114233 · Cited by 4
Stage‐dependent involvement of ADAM10 and its significance in epileptic seizures
Zhou, X., Tao, H., Cai, Y., Cui, L., Zhao, B., & Li, K. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14307 · Cited by 5
Svaldi, D. O., Higgins, I. A., Holdridge, K. C., Yaari, R., Case, M. G., Bracoud, L., Scott, D., Shcherbinin, S., & Sims, J. R. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12313 · Cited by 6
Self-citationMetabolic changes in the plasma of mild Alzheimer’s disease patients treated with Hachimijiogan
Kainuma, M., Kawakatsu, S., Kim, J., Ouma, S., Iritani, O., Yamashita, K.-I., Ohara, T., Hirano, S., Suda, S., Hamano, T., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1203349 · Cited by 7
“…studies of AD have reported that changes in phospholipids, polyamines, and amino acids have potential for use in diagnosis (Chouraki et al., 2017; Huo et al., 2020; Lin et al., 2019b; Olazarán et al., 2015; Orešič et al., 2011; Ozaki et al., 2022; Peña-Bautista et al., 2019; Shao et al., 2020;…”
BackgroundMethodMaeshige, N., Hayashi, H., Kawabe, N., Imaoka, S., Sakaki, S., Matsumoto, J., Kondo, E., Ishii, T., Kiyota, N., Furukawa, M., et al. (2023) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346231187178 · Cited by 4
“…rehabilitation programs; these included: (1) presence of neurologic impairments; (2) Mini-Mental State Examination score < 20 (moderate dementia) 33 ; (3) any discomfort or systemic health problem that may affect gait; and (4) major amputation (TTA) or severe post-operative complications…”
Nanoscale insights into the local structural rearrangements of amyloid-β induced by bexarotene
Sofińska, K., Batys, P., Cernescu, A., Ghosh, D., Skirlińska‐Nosek, K., Barbasz, J., Seweryn, S., Wilkosz, N., Riek, R., Szymoński, M., et al. (2023) · Nanoscale · doi:10.1039/d3nr01608k · Cited by 6
Mostafa, A., Tiu, S., Khan, F. A., & Baig, N. A. (2025) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_547_24 · Cited by 7
“One study focused on lecanemab (CLARITY AD), [11] two on aducanumab (EMERGE and ENGAGE), [12] three on solanezumab (EXPEDITION 1, 2, and 3), [13,14] two on bapineuzumab (STUDY 301 and STUDY 3000), [15,16] three on gantenerumab (SCARLET ROAD, GRADUATE I and II), [17,18] one on donanemab…”
InfluentialPassive Immunotherapy in Alzheimer’s Disease
Dolan, P. J., & Zago, W. M. (2018) · InTech eBooks · doi:10.5772/intechopen.76299 · Cited by 4
“Solanezumab, directed at an internal epitope of Aβ and hypothesized to function by binding soluble species in the CNS and periphery, failed a phase III trial in mild AD patients [33], and a trial conducted in prodromal patients was discontinued.”
Disease-Modification in Huntington’s Disease: Moving Away from a Single-Target Approach
Jensen, M. P., & Barker, R. A. (2019) · Journal of Huntington s Disease · doi:10.3233/jhd-180320 · Cited by 4
“In phase 3 trials [133, 134], solanezumab did not improve cognition or function in mild-to-moderate [133] and mild [134] AD, despite decreases in the CSF levels of unbound A (cid:2) , consistent with target engagement of soluble brain amyloid.”
Systematic Design of Drug Repurposing-Oriented Alzheimer’s Disease Ontology
Fang, L., Wang, M., Pham, H. A., Xiang, Y., Amith, M. “., Tao, C., Du, J., & Rao, G. (2019) · IEEE International Conference on Healthcare Informatics (ICHI) · doi:10.1109/ichi.2019.8904505 · Cited by 4
Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials
Tam, A., Laurent, C., Gauthier, S. G., & Dansereau, C. L. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.49 · Cited by 32
Aliffia, D., Ramadhani, D. A., Wasityastuti, W., Sari, D. R. T., Kustiati, U., Wihadmadyatami, H., & Kusindarta, D. L. (2023) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v15i4.2415 · Cited by 9
“(7) Numerous studies to investigate antibody-based treatment with the Aβ peptide as a target, such as ponezumab (8), solanezumab (9), gantenerumab (10), crenezumab (11) have already been done.”
Alzheimer’s Disease: Treatment Today and Tomorrow
Gorthi, S. P., & Gupta, D. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_254_23 · Cited by 5
“Salloway et al. [23] in 2014 and Vandenberghe et al. [24] in 2016 evaluated bapineuzumab in six studies, Doody et al. [25] in 2014 and Hongi et al. [26] in 2018 studied solanezumab tested in three Randomized Control Trials (RCTs), Ostrowitzki et al. [27] in 2017 studied gantenerumab in two studies,…”
Noguchi‐Shinohara, M., & Ono, K. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4604-24 · Cited by 4
“A phase 3 clinical trial on solanezumab was conducted in 2,129 patients with mild dementia and AD (11).”
Future directions in animal models of Alzheimer’s disease
Beckman, D., Baxter, M. G., & Morrison, J. H. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24328 · Cited by 4
“Solanezumab showed potential results in transgenic mice but was unsuccessful in several clinical trials, including the new published double‐blind placebo‐controlled phase 3 trial (Honig, 2018).”
BackgroundRefining the understanding of typical Alzheimer disease
Jessen, F. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0259-0 · Cited by 5
Pragmatic Trials and Repurposed Drugs for Alzheimer Disease
Schneider, L. S. S. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3784 · Cited by 6
Chandler, J. M., Lansdall, C. J., Ye, W., McDougall, F., Belger, M. A., Toth, B., Mi, X., Sink, K. M., & Atkins, A. S. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100261 · Cited by 3
An, D., Zou, X., & Xu, Y. (2025) · Current Neuropharmacology · doi:10.2174/011570159x391766250806091602 · Cited by 3
“Both Crenezumab (CREAD trial) and Solanezumab (EXPEDI-TION trial) failed to show significant amyloid plaque reduction on PET imaging [71, 72].”
kherchouche, A., Ahmed, O. B., Guillevin, C., Tremblais, B., Julian, A., & Guillevin, R. (2022) · Proceedings - International Conference on Image Processing · doi:10.1109/icip46576.2022.9897601 · Cited by 4
“Indeed, the MCI case lies on a spectrum between NC and manifest AD while the MAD is the next stage after the MCI condition [4].”
Background
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.